Healthcare Finance News March 3, 2022
Susan Morse

Attorneys representing insulin purchasers against Sanofi, Novo Nordisk and Eli Lilly say they have filed a motion for class certification.

Much of the stakeholder reaction to healthcare initiatives in President Joe Biden’s State of the Union address on Tuesday centered on the president’s repeated urging to Congress to allow Medicare to negotiate drug prices.

“That is why my top priority is getting prices under control,” Biden said Tuesday night. “We pay more for the same drug produced by the same company than any other country in the world.” 

Biden put the spotlight on insulin, which he said costs about $10 a vial to make. But drug makers charge 30 times that amount, said Biden, who wants to cap the cost...

Today's Sponsors

Institute for Healthcare Improvement
Crossover Health

Today's Sponsors

Patient Bond

Today's Sponsor


Topics: Biotechnology, Govt Agencies, Healthcare System, Pharma, Pharma / Biotech, Pricing / Spending
Study: Many digital health startups lack clinical trials, regulatory filings
Mark Cuban's generic drug prices would save Medicare billions of dollars: Harvard study
Washington ups pressure on PBMs with more aggressive FTC policy, congressional ask for GAO study
$3 Billion in Cancer Drug Waste: Can It Be Salvaged?
Building a stronger opioid stewardship program that Includes drug diversion prevention